The contribution of Asian researchers to the field of rheumatology

Nature Reviews Rheumatology

Volumn 6, Issue 2, 2010, Pages 106-111

  Yamano, Yoshihisa ^a   Nishioka, Kusuki ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; FAS ANTIBODY; FAS ANTIGEN; HLA B ANTIGEN; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; SYNOVIOLIN; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADULT ONSET STILL DISEASE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AORTA ARCH SYNDROME; APOPTOSIS; ASIA; AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOPATHOLOGY; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL RESEARCH; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PREVOTELLA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; SYNOVIOCYTE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TREATMENT RESPONSE;

ASIA; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 76649143393     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.257     Document Type: Review

References (61)

1. Zeng, Q. Y. et al. rheumatic diseases in China. Arthritis Res. Ther. 10, r17 (2008).
2. Omurzakova, N. A. et al. High incidence of rheumatic fever and rheumatic heart disease in the republics of Central Asia. Int. J. Rheumatic Dis. 12, 79-83 (2009).
3. Yazici, H., Fresko, I. & Yurdakul, S. Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat. Clin. Pract. Rheumatol. 3, 148-155 (2007).
4. Osame, M. et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1, 1031-1032 (1986). (Pubitemid 16102987)
5. Nishioka, K. et al. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1, 441 (1989).
6. Mochizuki, M. et al. Uveitis associated with human T-cell lymphotropic virus type I. Am. J. Ophthalmol. 114, 123-129 (1992).
7. Maruyama, I., Mori, S., Kawabata, M. & Osame, M. Bronchopneumonopathy in HTLV-1 associated myelopathy (HAM) and non-HAM HTLV-1 carriers [Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi 30, 775-779 (1992).
8. Nakagawa, M. et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J. Neurovirol. 1, 50-61 (1995).
9. Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007).
10. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
11. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. regulatory T cells and immune tolerance. Cell 133, 775-787 (2008).
12. Yagishita, N., Yamasaki, S., Nishioka, K. & Nakajima, T. Synoviolin, protein folding and the maintenance of joint homeostasis. Nat. Clin. Pract. Rheumatol. 4, 91-97 (2008).
13. Yamada, r. & Yamamoto, K. Mechanisms of disease: genetics of rheumatoid arthritis- ethnic differences in disease-associated genes. Nat. Clin. Pract. Rheumatol. 3, 644-650 (2007).
14. Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2, 619-626 (2006).
15. Behçet, H. Uber rezidivierende, aphthose, dürch ein Virus verursachte Geshwure am Munde, am Auge und an den Genitalien. Dermatologische Wochenschrift 36, 1152-1157 (1937).
16. Verity, D. H., Marr, J. e., Ohno, S., wallace, G. r. & Stanford, M. r. Behçet's disease, the Silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54, 213-220 (1999).
17. Hatemi, G. et al. The pustular skin lesions in Behcet's syndrome are not sterile. Ann. Rheum. Dis. 63, 1450-1452 (2004).
18. Gul, A. Behcet's disease as an autoinflammatory disorder. Curr. Drug Targets Inflamm. Allergy 4, 81-83 (2005).
19. Numano, F. The story of Takayasu arteritis. Rheumatology (Oxford) 41, 103-106 (2002).
20. Koide, K. Takayasu arteritis in Japan. Heart Vessels Suppl. 7, 48-54 (1992).
21. Arend, w. P. et al. The American College of rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 33, 1129-1134 (1990).
22. Kimura, A., Kitamura, H., Date, Y. & Numano, F. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int. J. Cardiol. 54 (Suppl.), S61-S69 (1996).
23. Seko, Y. et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J. Clin. Invest. 93, 750-758 (1994).
24. Huang, w. C. et al. epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 123, e401-e405 (2009).
25. Holman, r. C., Curns, A. T., Belay, e. D., Steiner, C. A. & Schonberger, L. B. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 112, 495-501 (2003).
26. Burns, J. C. et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology 16, 220-225 (2005).
27. Onouchi, Y. et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet. 40, 35-42 (2008).
28. Birmann, B. M. et al. Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica. Int. J. Cancer 124, 614-621 (2009).
29. Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K. & Uchino, H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50, 481-492 (1977).
30. Nishioka, K., Sumida, T. & Hasunuma, T. Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Arthritis Rheum. 39, 1410-1418 (1996).
31. Yamano, Y. et al. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J. Clin. Invest. 115, 1361-1368 (2005).
32. Nakajima, T. et al. Overgrowth of human synovial cells driven by the human T cell leukemia virus type I tax gene. J. Clin. Invest. 92, 186-193 (1993).
33. Iwakura, Y. et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 253, 1026-1028 (1991).
34. Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83, 170-179 (2005).
35. Sato, K. & Takayanagi, H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18, 419-426 (2006).
36. Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 40, 251-264 (2007).
37. Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
38. Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signaling crosstalk between rANKL and IFN-gamma. Nature 408, 600-605 (2000).
39. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
40. Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899-911 (2009).
41. Yamano, Y. et al. Abnormally high levels of virusinfected IFN-γ+CCr4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One 4, e6517 (2009).
42. Amano. T. et al. Synoviolin/Hrd1, an e3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes Dev. 17, 2436-2449 (2003).
43. Schroder, M. & Kaufman, r. J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789 (2005).
44. Yamasaki, S. et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 26, 113-122 (2007).
45. Toh, M. L. et al. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum. 54, 2109-2118 (2006).
46. Sato, K. et al. reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993).
47. Nishimoto, N. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATOrI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19, 12-19 (2009).
48. Smolen, J. S. et al. effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997 (2008).
49. Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968-2980 (2008).
50. emery, P. et al. IL-6 receptor inhibition with tocilizmab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicentre randomized placebocontrolled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
51. raff, M. C. Social controls on cell survival and cell death. Nature 356, 397-400 (1992).
52. Yonehara, S., Ishii, A. & Yonehara, M. A cellkilling monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747-1756 (1989).
53. Nagata, S. Apoptosis by death factor. Cell 88, 355-365 (1997).
54. Nishioka, K., Hasunuma, T., Kato, T., Sumida, T. & Kobata, T. Apoptosis in rheumatoid arthritis: a novel pathway in the regulation of synovial tissue. Arthritis Rheum. 41, 1-9 (1998). (Pubitemid 28041916)
55. Cantwell, M. J., Hua, T., Zvaifler, N. J. & Kipps, T. J. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 40, 1644-1652 (1997).
56. Kobayashi, T. et al. Differential regulation of Fasmediated apoptosis of rheumatoid synoviocytes by tumor necrosis factor alpha and basic fibroblast growth factor is associated with the expression of apoptosis-related molecules. Arthritis Rheum. 43, 1106-1114 (2000).
57. Salmon, M. et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99, 439-446 (1997).
58. Perlman, H. et al. rheumatoid arthritis synovial macrophages express the Fas-associated death domain-like interleukin-1β-converting enzymeinhibitory protein and are refractory to Fasmediated apoptosis. Arthritis Rheum. 44, 21-30 (2001).
59. Fujisawa, K. et al. Therapeutic effect of the anti- Fas antibody on arthritis in HTLV-1 tax transgenic mice. J. Clin. Invest. 98, 271-278 (1996).
60. Matsuno, H. et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J. Rheumatol. 29, 1609-1614 (2002).
61. Appelboom, T. et al. Preliminary results of a phase I clinical trial of intra-articular administration of ArG098, a novel anti-Fas IgM Mab, in rA [presentation number 421]. Presented at the ACr/ArHP Scientific Meeting, Philadelphia, PA (18 October 2009).